Johnson & Johnson (JNJ) Other Working Capital Changes (2009 - 2026)
Johnson & Johnson (JNJ) posted Other Working Capital Changes of -$950.0 million for Q2 2026, down 172.21% sequentially from -$349.0 million in Q1 2026, and down 119.48% YoY from $4.9 billion in Q2 2025.
Johnson & Johnson (JNJ) Other Working Capital Changes (2009 - 2026) Analysis & Trends
Johnson & Johnson has reported Other Working Capital Changes for 18 years, with the latest figure at -$950.0 million in Q2 2026.
- Quarterly Other Working Capital Changes fell 119.48% year-over-year to -$950.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$1.3 billion (down 116.15% YoY) and the FY2025 annual result came in at $6.2 billion, up 459.17% from the prior year.
- Other Working Capital Changes declined to -$950.0 million in Q2 2026 per JNJ's latest filing, from -$349.0 million in the prior quarter.
- Over five years, Other Working Capital Changes peaked at $4.9 billion in Q2 2025 and troughed at -$3.2 billion in Q1 2024.
- A 5-year average of $439.4 million and a median of $225.5 million in 2023 frame the typical range for Other Working Capital Changes.
- The widest YoY moves for Other Working Capital Changes: up 1153.15% in 2024, down 449.62% in 2024.
- Over 5 years, Other Working Capital Changes stood at -$995.0 million in 2022, then surged by 312.46% to $2.1 billion in 2023, then plunged by 136.33% to -$768.0 million in 2024, then tumbled by 93.49% to -$1.5 billion in 2025, then surged by 36.07% to -$950.0 million in 2026.
- According to Business Quant data, Other Working Capital Changes over the past three periods registered -$950.0 million, -$349.0 million, and -$1.5 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | -950.00 Mn |
| Jun 28, 2026 | -950.00 Mn |
| Jun 28, 2026 | -950.00 Mn |
| Mar 29, 2026 | -349.00 Mn |
| Mar 29, 2026 | -349.00 Mn |
| Mar 29, 2026 | -349.00 Mn |
| Dec 28, 2025 | -1.49 Bn |
| Dec 28, 2025 | -1.49 Bn |
| Dec 28, 2025 | -1.49 Bn |
| Sep 28, 2025 | 1.46 Bn |
| Sep 28, 2025 | 1.46 Bn |
| Sep 28, 2025 | 1.46 Bn |
| Jun 29, 2025 | 4.88 Bn |
| Jun 29, 2025 | 4.88 Bn |
| Jun 29, 2025 | 4.88 Bn |
| Mar 30, 2025 | 1.32 Bn |
| Mar 30, 2025 | 1.32 Bn |
| Mar 30, 2025 | 1.32 Bn |
| Dec 29, 2024 | -768.00 Mn |
| Dec 29, 2024 | -768.00 Mn |